<s>[INST] A team of researchers has developed a novel antibiotic that is highly effective against bacterial infections. However, the researchers soon discover that the antibiotic also has a unique side effect: it causes the patient's skin to temporarily turn a bright shade of blue. Despite this side effect, the researchers believe that the antibiotic is still safe and effective for treating serious bacterial infections. The researchers have applied for FDA approval, but the agency has expressed concern about the blue skin side effect and its potential impact on patient quality of life. The FDA is considering whether to approve the antibiotic, but only if the researchers can demonstrate that the benefits of the antibiotic outweigh the risks associated with the blue skin side effect. 

What would be the appropriate course of action for the researchers and the FDA?[/INST]